Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Colorectal Neoplasms

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 100 articles: HTML format

Single Articles

July 2026
1. HEATER N, Catalano PJ, Benson AB 3rd
   Beyond R2: Assessing quality of trial level surrogate endpoints in colorectal cancer.
   J Natl Cancer Inst. 2026 Jul 2:djag170. doi: 10.1093.
   PubMed    
   
   
   
2. MULLANY LC, Emmert AD, Ramirez SH, Babin SM, et al
   Deployment to Karshi-Khanabad Air Base, Uzbekistan between 2001 and 2005 and subsequent risk of specific cancers among US service members.
   J Natl Cancer Inst. 2026;118:1238-1247.
   PubMed     Abstract available
   
   
   June 2026
3. SUNG H, Kelly K, Jiang C, Laversanne M, et al
   Trends in colorectal cancer mortality among younger versus older adults in 49 countries.
   J Natl Cancer Inst. 2026 Jun 23:djag153. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. POTTER AL, Kothagundla S, Guo Q, Cheney B, et al
   Millions of adults undergoing breast and colorectal cancer screening are eligible for lung cancer screening, but do not get screened.
   J Natl Cancer Inst. 2026 Jun 5:djag176. doi: 10.1093.
   PubMed     Abstract available
   
   
   May 2026
5. RAIMONDI A, Tine G, Boige V, Ballhausen A, et al
   Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancer.
   J Natl Cancer Inst. 2026 May 22:djag160. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. MADDALENA G, van der Pol Y, Villarreal OE, Coker O, et al
   Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab.
   J Natl Cancer Inst. 2026;118:903-908.
   PubMed     Abstract available
   
   
   April 2026
7. GAWDI R, Sjolander EN, Lee JS, Whelan RL, et al
   Evaluating the role of medicaid expansion on survival in early onset colorectal cancer.
   J Natl Cancer Inst. 2026 Apr 6:djag109. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. CAMPOY S, Drouet Y, Rochefort P, Bonadona V, et al
   Cancer risks in Lynch syndrome carriers: a systematic review and meta-analysis.
   J Natl Cancer Inst. 2026;118:589-602.
   PubMed     Abstract available
   
   
   March 2026
9. CHIA BJ, Allegra C, Krishnamurthi S, Lieu C, et al
   A framework to evaluate surrogate endpoints at the trial level: Analysis in colorectal cancer.
   J Natl Cancer Inst. 2026 Mar 23:djag088. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. PISCITELLO AJ, Edwards V DK, Fransen S, Meester RGS, et al
    RE: the centers for medicare and medicaid services and others misunderstand stool testing for colorectal cancer.
    J Natl Cancer Inst. 2026 Mar 17:djag074. doi: 10.1093.
    PubMed    
    
    
    
11. OPHOFF D, Bos D, van Heek T, Witteman BJ, et al
    Liver fat and clinical outcomes in individuals with stage I-III colon or rectal cancer.
    J Natl Cancer Inst. 2026;118:466-475.
    PubMed     Abstract available
    
    
    
12. BRENNER H, Holland-Letz T, Kopp-Schneider A, Heisser T, et al
    Early-detection and prevention effects of screening sigmoidoscopy: evidence from randomized trials revisited.
    J Natl Cancer Inst. 2026;118:422-428.
    PubMed     Abstract available
    
    
    February 2026
13. 
    Correction to: Changing paradigms in colorectal cancer screening.
    J Natl Cancer Inst. 2026 Feb 17:djag010. doi: 10.1093.
    PubMed    
    
    
    
14. HUANG BZ, Chen F, Bogumil D, Han S, et al
    Interaction of genetic and lifestyle risk scores on colorectal cancer risk across five racial and ethnic populations.
    J Natl Cancer Inst. 2026 Feb 16:djag045. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. RUTTER CM, Maerzluft CE, Matrajt L, Nascimento de Lima P, et al
    CRC-SPIN version 3.0: an updated policy model for colorectal cancer screening that includes the serrated pathway.
    J Natl Cancer Inst. 2026 Feb 16:djag037. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. YASINZAI AQK, Jalali P, Syaj S, Sahin IH, et al
    Trends and projected burden of early-onset gastrointestinal malignancies in the United States: a population-based analysis (2001-2021).
    J Natl Cancer Inst. 2026;118:250-260.
    PubMed     Abstract available
    
    
    January 2026
17. COURNEYA KS, Booth CM, Vardy JL, Friedenreich CM, et al
    Effects of a structured exercise program on motivational outcomes in patients with Colon cancer.
    J Natl Cancer Inst. 2026 Jan 29:djag023. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. PINSKY PF
    Endoscopic screening for colorectal cancer: efficacy versus effectiveness.
    J Natl Cancer Inst. 2026 Jan 20:djaf384. doi: 10.1093.
    PubMed    
    
    
    
19. LIEBERMAN D
    Centers for Medicare and Medicaid and colorectal cancer screening test standards: time for a change.
    J Natl Cancer Inst. 2026 Jan 16:djaf367. doi: 10.1093.
    PubMed    
    
    
    
20. SHAUKAT A, Meng Z, Kutnik K, Sun CK, et al
    Age- and sex-adjusted performance of a colorectal cancer screening test using US census distribution.
    J Natl Cancer Inst. 2026 Jan 9:djag007. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. WESTVOLD SJ, Long JB, Fan J, Kc M, et al
    Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer.
    J Natl Cancer Inst. 2026;118:130-140.
    PubMed     Abstract available
    
    
    
22. BAILEY JT, Chang CJ, Gaston SA, Jackson CL, et al
    Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers.
    J Natl Cancer Inst. 2026;118:94-101.
    PubMed     Abstract available
    
    
    December 2025
23. YU Z
    RE: a prediction model for metachronous colorectal cancer: development and validation.
    J Natl Cancer Inst. 2025 Dec 13:djaf351. doi: 10.1093.
    PubMed    
    
    
    
24. BOIGE V, Menoret E, Le Teuff G, Boyer JC, et al
    A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.
    J Natl Cancer Inst. 2025 Dec 12:djaf357. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. CORONADO GD, Hoffman RM, Llavona-Ortiz J, Rutter CM, et al
    The Centers for Medicare and Medicaid Services and others misunderstand stool testing for colorectal cancer.
    J Natl Cancer Inst. 2025 Dec 1:djaf341. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2025
26. WU T, Ou Q, Xu H, Chen Y, et al
    Prediagnostic dietary phytosterol intake, inflammatory biomarkers, and colorectal cancer survival: a cohort study.
    J Natl Cancer Inst. 2025 Nov 10:djaf325. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. CHEN KL, Mangione CM, Shih YT
    Unmet social needs and colorectal cancer testing at 45-49 since the 2021 USPSTF recommendation.
    J Natl Cancer Inst. 2025 Nov 9:djaf318. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. LIU Q, Wiese D, Pinheiro PS, Bispo JB, et al
    Association between racialized economic segregation and stage at diagnosis for 3 screenable cancers in New York City.
    J Natl Cancer Inst. 2025;117:2259-2271.
    PubMed     Abstract available
    
    
    October 2025
29. ZHAO Y, Nogueira MS, Milne GL, Gao YT, et al
    Time-dependent relationship between urinary biomarkers of nucleic acid oxidation and colorectal cancer risk.
    J Natl Cancer Inst. 2025 Oct 31:djaf312. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. BASU P
    Changing paradigms in colorectal cancer screening.
    J Natl Cancer Inst. 2025 Oct 11:djaf267. doi: 10.1093.
    PubMed    
    
    
    
31. MEESTER RGS, Piscitello AJ, Duimstra JA, Liang PS, et al
    Comparative benefits, burdens and harms of emerging blood-based tests for colorectal cancer screening.
    J Natl Cancer Inst. 2025 Oct 6:djaf277. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. EBNER DW, Fendrick AM, Kisiel JB, Estes C, et al
    Evaluating benefit-to-burden ratios of the established and emerging colorectal cancer screening strategies.
    J Natl Cancer Inst. 2025 Oct 1:djaf209. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. EBNER DW, Estes C, Limburg PJ
    RE: Evaluating benefit-to-burden ratios of the established and emerging colorectal cancer screening strategies.
    J Natl Cancer Inst. 2025 Oct 1:djaf266. doi: 10.1093.
    PubMed    
    
    
    
34. BRAY F, Laversanne M
    Stat Bite: recent trends in colon cancer incidence at ages 25-49 vs 50-74 in 50 countries.
    J Natl Cancer Inst. 2025;117:2146-2147.
    PubMed    
    
    
    
35. IFHAM HANIF M, Sholihah MM
    RE: Effects of a high-fiber, high-fruit, and high-vegetable, low-fat dietary intervention on the rectal tissue microbiome.
    J Natl Cancer Inst. 2025;117:2142-2143.
    PubMed     Abstract available
    
    
    September 2025
36. CHENG E, Shi Q, Shields AF, Xue X, et al
    Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (alliance).
    J Natl Cancer Inst. 2025 Sep 25:djaf281. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. MEESTER RGS, Miller EA, Pinsky PF, Schoen RE, et al
    Contrasts in colorectal cancer incidence and mortality in screening trials of sigmoidoscopy versus colonoscopy (NordICC).
    J Natl Cancer Inst. 2025 Sep 14:djaf269. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. HAAS JS, Todd KW, Mclerran D, Tiro JA, et al
    Gaps in care across the cancer screening continuum for cervical, colorectal and lung cancer.
    J Natl Cancer Inst. 2025 Sep 10:djaf248. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. KOKER G, Ozcelik G
    RE: Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women.
    J Natl Cancer Inst. 2025 Sep 3:djaf252. doi: 10.1093.
    PubMed    
    
    
    
40. KAZEMIAN E, Mo Q, Matejcic M, Tsai YY, et al
    Genetic predisposition to persistent fatigue after a diagnosis of colorectal cancer.
    J Natl Cancer Inst. 2025 Sep 1:djaf140. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
41. DOWNHAM L, Laversanne M, Perdomo S, Filho AM, et al
    Increase of early-onset colorectal cancer: a cohort effect.
    J Natl Cancer Inst. 2025 Aug 23:djaf238. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. MAJOR A, Chou J, Lam H, Kim KE, et al
    Mortality after colorectal cancer among survivors of childhood cancer.
    J Natl Cancer Inst. 2025 Aug 21:djaf127. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. ZAANAN A, Bergen ES, Evesque L, Meurisse A, et al
    Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study.
    J Natl Cancer Inst. 2025 Aug 20:djaf229. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. DUHOKY R, Geitenbeek RTJ, Niccolo Piozzi G, Burghgraef TA, et al
    Ten years of robot-assisted versus laparoscopic total mesorectal excision for rectal cancer (short-term RESOLUTION).
    J Natl Cancer Inst. 2025;117:1614-1626.
    PubMed     Abstract available
    
    
    
45. FULLER S, Alexeeff S, Caan B, Goncalves MD, et al
    Early identification of weight loss trajectories in advanced cancer and associations with survival.
    J Natl Cancer Inst. 2025;117:1729-1732.
    PubMed     Abstract available
    
    
    July 2025
46. NASCIMENTO DE LIMA P, Bartholomew L, May FP, Coronado GD, et al
    The triple-effect of colorectal cancer screening: reducing deaths, government spending and mortality disparities.
    J Natl Cancer Inst. 2025 Jul 30:djaf202. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. ZHANG Y, Karahalios A, Win AK, Makalic E, et al
    A prediction model for metachronous colorectal cancer: development and validation.
    J Natl Cancer Inst. 2025 Jul 16:djaf191. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. LIEBERMAN D, Ladabaum U
    Non-invasive colorectal cancer screening: simple may be optimal.
    J Natl Cancer Inst. 2025 Jul 7:djaf171. doi: 10.1093.
    PubMed    
    
    
    
49. XU J, Lou T, Xu L
    RE: Post-diagnosis dietary and lifestyle factors and mortality outcomes among colorectal cancer patients: a meta-analysis.
    J Natl Cancer Inst. 2025 Jul 4:djaf168. doi: 10.1093.
    PubMed    
    
    
    
50. HUANG YJ, Lin JA, Chen WM, Shia BC, et al
    Metformin use and risk of colorectal cancer in patients with inflammatory bowel disease: a nationwide, Population-Based cohort study.
    J Natl Cancer Inst. 2025 Jul 2:djaf165. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. ALVAREZ J, Zambare W, George M, Garcia R, et al
    Utilizing Patient Input in Rectal Cancer Trial Design.
    J Natl Cancer Inst. 2025;117:1421-1428.
    PubMed     Abstract available
    
    
    
52. BLEYER A, Ries LAG, Cameron DB, Mansfield SA, et al
    Colon, colorectal, and all cancer incidence increase in the young due to appendix reclassification.
    J Natl Cancer Inst. 2025;117:1340-1349.
    PubMed     Abstract available
    
    
    
53. FAN Q, Dong W, Schafer EJ, Wagle NS, et al
    Changes in time-to-treatment initiation for breast, non-small cell lung, colon, or rectal cancers throughout the COVID-19 pandemic in the United States.
    J Natl Cancer Inst. 2025;117:1506-1511.
    PubMed     Abstract available
    
    
    June 2025
54. HARLASS M, Knudsen AB, Nieboer D, van Duuren LA, et al
    Benefits of colorectal cancer screening using FIT with varying positivity thresholds by age and sex.
    J Natl Cancer Inst. 2025 Jun 23:djaf149. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. ZAMAN FY, Orchard SG, Polekhina G, Gibbs P, et al
    Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults.
    J Natl Cancer Inst. 2025 Jun 14:djaf145. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. YARMOLINSKY J, Lee MA, Lau E, Moratalla-Navarro F, et al
    Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention.
    J Natl Cancer Inst. 2025 Jun 13:djaf137. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. OVEISI N, Sayre EC, Brotto LA, Cheng V, et al
    Sexual health outcomes after colorectal cancer diagnosis in females: a population-based cohort study.
    J Natl Cancer Inst. 2025 Jun 1:djaf120. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. BYRD DA, Gomez M, Hogue S, Wan Y, et al
    Effects of a high-fiber, high-fruit and high-vegetable, low-fat dietary intervention on the rectal tissue microbiome.
    J Natl Cancer Inst. 2025;117:1237-1244.
    PubMed     Abstract available
    
    
    May 2025
59. 
    Correction to: Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    J Natl Cancer Inst. 2025 May 30:djaf124. doi: 10.1093.
    PubMed    
    
    
    
60. CHAR SK, Chan JA, Ng K
    Rising incidence of early-onset colorectal cancer: impact of anatomy and histology.
    J Natl Cancer Inst. 2025 May 29:djaf094. doi: 10.1093.
    PubMed    
    
    
    
61. CHEN QY, Keum N, Giovannucci EL
    Post-diagnosis dietary and lifestyle factors and mortality outcomes among colorectal cancer patients: a meta-analysis.
    J Natl Cancer Inst. 2025 May 2:djaf098. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. SOERJOMATARAM I, Bardot A, Bray F
    Stat Bite: Surviving or dying from colon cancer or other causes 5 years after diagnosis, Australia 2010-2014, females.
    J Natl Cancer Inst. 2025;117:1090-1091.
    PubMed    
    
    
    April 2025
63. TSEGAYE AT, Shing JZ, Vo JB, Kreimer AR, et al
    Racial and ethnic differences in HPV-related cancer incidence in the United States, 2001-2020.
    J Natl Cancer Inst. 2025 Apr 26:djaf107. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. MURPHY CC, Dias EM, Cirillo PM, Krigbaum NY, et al
    Father's occupation and colorectal cancer in his adult offspring.
    J Natl Cancer Inst. 2025 Apr 24:djaf104. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. KUMAR R, Hallemeier CL, Chang DT, Lu SE, et al
    Increased occurrence of malignancy before and after chemoradiation for anal squamous cell carcinoma: a multi-institutional analysis.
    J Natl Cancer Inst. 2025;117:772-780.
    PubMed     Abstract available
    
    
    
66. SANTUCCI C, Mignozzi S, Alicandro G, Pizzato M, et al
    Trends in cancer mortality under age 50 in 15 upper-middle and high-income countries.
    J Natl Cancer Inst. 2025;117:747-760.
    PubMed     Abstract available
    
    
    February 2025
67. LIU Y, Song M, Giovannucci EL, Platz EA, et al
    Pre- and post-diagnostic use of antihypertensive medications and stage I-III colorectal cancer survival: prospective cohort study.
    J Natl Cancer Inst. 2025 Feb 25:djaf046. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. HU P, Prorok PC, Katki HA
    Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening.
    J Natl Cancer Inst. 2025;117:303-311.
    PubMed     Abstract available
    
    
    
69. TROESTER A, Parikh R, Southwell B, Ester E, et al
    Treatment of stage I-III squamous cell anal cancer: a comparative effectiveness systematic review.
    J Natl Cancer Inst. 2025;117:240-252.
    PubMed     Abstract available
    
    
    January 2025
70. MEZGER NCS, Seraphin TP, Balle R, Griesel M, et al
    NCCN guideline-concordant cancer care in sub-Saharan Africa: a population-based multicountry study of 5 cancers.
    J Natl Cancer Inst. 2025;117:120-133.
    PubMed     Abstract available
    
    
    December 2024
71. HU Q, Yang X, Sun Y
    Re: Characteristics of a cost-effective blood test for colorectal cancer screening.
    J Natl Cancer Inst. 2024 Dec 24:djae340. doi: 10.1093.
    PubMed    
    
    
    
72. LI X, Hur J, Zhang Y, Song M, et al
    Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women.
    J Natl Cancer Inst. 2024 Dec 17:djae330. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2024
73. JUDGE SJ, Malekzadeh P, Corines MJ, Gollub MJ, et al
    Watch and wait in rectal cancer patients with residual mucin on magnetic resonance imaging following neoadjuvant therapy.
    J Natl Cancer Inst. 2024;116:1761-1766.
    PubMed     Abstract available
    
    
    October 2024
74. DOWNIE JM, Joshi AD, Geraghty CM, Guercio BJ, et al
    Novel metabolomic predictors of incident colorectal cancer in men and women.
    J Natl Cancer Inst. 2024 Oct 28:djae270. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. HU Q, Zhou X, Sun Y
    RE: Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).
    J Natl Cancer Inst. 2024 Oct 16:djae257. doi: 10.1093.
    PubMed    
    
    
    
76. VAN DEN PUTTELAAR R, Shi KS, Smith R, Zhao J, et al
    Implications of the initial braidwood v. Becerra ruling for colorectal cancer outcomes: a modeling study.
    J Natl Cancer Inst. 2024 Oct 3:djae244. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1675-1682.
    PubMed     Abstract available
    
    
    September 2024
78. ZHAO J, Xue E, Zhou S, Zhang M, et al
    Allostatic Load, Genetic Susceptibility, Incidence Risk, and All-cause Mortality of Colorectal Cancer.
    J Natl Cancer Inst. 2024 Sep 13:djae223. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. GARG A, Damgacioglu H, Sigel K, Nyitray AG, et al
    Future patterns in burden and incidence of squamous cell carcinoma of the anus in the United States, 2001-2035.
    J Natl Cancer Inst. 2024;116:1508-1512.
    PubMed     Abstract available
    
    
    
80. DESHMUKH AA, Lin YY, Damgacioglu H, Shiels M, et al
    Recent and projected incidence trends and risk of anal cancer among people with HIV in North America.
    J Natl Cancer Inst. 2024;116:1450-1458.
    PubMed     Abstract available
    
    
    August 2024
81. CHENG E, Ou FS, Gatten C, Ma C, et al
    Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer.
    J Natl Cancer Inst. 2024 Aug 30:djae213. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. BROWN JC, Ma C, Shi Q, Couture F, et al
    Inflammation, Physical Activity, and Disease-Free Survival in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
    J Natl Cancer Inst. 2024 Aug 24:djae203. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. LIANG PS, Bhatt D
    Modeling disparities in colorectal cancer outcomes: colonoscopy follow-up and quality are key.
    J Natl Cancer Inst. 2024 Aug 8:djae176. doi: 10.1093.
    PubMed    
    
    
    
84. RIM SH, Beer L, Saraiya M, Tie Y, et al
    Prevalence of anal cytology screening among persons with HIV and lack of access to high-resolution anoscopy at HIV care facilities.
    J Natl Cancer Inst. 2024;116:1319-1332.
    PubMed     Abstract available
    
    
    
85. GUPTA A, O'Callaghan CJ, Zhu L, Jonker DJ, et al
    The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17.
    J Natl Cancer Inst. 2024;116:1313-1318.
    PubMed     Abstract available
    
    
    
86. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed     Abstract available
    
    
    
87. BERRY E, Hostetter J, Bachtold J, Zamarripa S, et al
    Evaluating colonoscopy quality by performing provider type.
    J Natl Cancer Inst. 2024;116:1264-1269.
    PubMed     Abstract available
    
    
    July 2024
88. ALAGOZ O, May FP, Doubeni CA, Fendrick AM, et al
    Impact of racial disparities in follow-up and quality of colonoscopy on colorectal cancer outcomes.
    J Natl Cancer Inst. 2024 Jul 24:djae140. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2024
89. TSAI YY, Nair KG, Barot SV, Xiang S, et al
    Differences in Tumor-Associated T cell receptor repertoires between Early-Onset and Average-Onset colorectal cancer.
    J Natl Cancer Inst. 2024 Jun 20:djae143. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. SONG Y, Loomans-Kropp H, Baugher RN, Somerville B, et al
    Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome.
    J Natl Cancer Inst. 2024;116:957-965.
    PubMed     Abstract available
    
    
    
91. YATES J, Schaufelberger H, Steinacher R, Schar P, et al
    DNA-methylation variability in normal mucosa: a field cancerization marker in patients with adenomatous polyps.
    J Natl Cancer Inst. 2024;116:974-982.
    PubMed     Abstract available
    
    
    
92. RANSOHOFF DF
    Evaluating a blood test for Colon cancer screening: how simulation modeling can inform clinical policy making and research.
    J Natl Cancer Inst. 2024 Jun 6:djae125. doi: 10.1093.
    PubMed    
    
    
    
93. NASCIMENTO DE LIMA P, Van Den Puttelaar R, Knudsen AB, Hahn AI, et al
    Characteristics of a cost-effective blood test for colorectal cancer screening.
    J Natl Cancer Inst. 2024 Jun 6:djae124. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
94. HOCHSTER HS, Catalano P, Weitz M, Mitchell EP, et al
    Combining anti-VEGFR and anti-EGFR antibodies: Randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer:(ECOG-ACRIN E7208).
    J Natl Cancer Inst. 2024 May 22:djae114. doi: 10.1093.
    PubMed     Abstract available
    
    
    
95. CORONADO GD, Bienen L, Burnett-Hartman A, Lee JK, et al
    Maximizing scarce colonoscopy resources: the crucial role of stool-based tests.
    J Natl Cancer Inst. 2024;116:647-652.
    PubMed     Abstract available
    
    
    April 2024
96. SUN J, Zhao J, Zhou S, Li X, et al
    Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer.
    J Natl Cancer Inst. 2024 Apr 22:djae089. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. FANG A, Ugai T, Gurjao C, Zhong R, et al
    Alcohol and colorectal cancer risk subclassified by mutational signatures of DNA mismatch repair deficiency.
    J Natl Cancer Inst. 2024 Apr 4:djae078. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
98. BEVER AM, Hang D, Lee DH, Tabung FK, et al
    Metabolomic signatures of inflammation and metabolic dysregulation in relation to colorectal cancer risk.
    J Natl Cancer Inst. 2024 Mar 1:djae047. doi: 10.1093.
    PubMed     Abstract available
    
    
    
99. GOPALANI SV, Saraiya M, Huang B, Tucker TC, et al
    Population-level incidence of HPV-positive oropharyngeal, cervical, and anal cancers by smoking status.
    J Natl Cancer Inst. 2024 Mar 1:djae054. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2023
100. HAAS CB, Engels EA, Horner MJ, Pfeiffer RM, et al
     Cumulative incidence of anal cancer since HIV or AIDS diagnosis in the United States.
     J Natl Cancer Inst. 2023;115:1227-1230.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum